Peter Marks continues to sketch a pathway to market for pediatric gene therapies in rare diseases that could be faster than traditional product development and not require a randomized clinical trial.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?